Rheumatology
Novel study design, open dialogue on drug development critical to JIA drug pipeline
Opening dialogue between regulatory agencies, pharmaceutical companies and clinicians to develop and implement novel clinical trial designs could be one possible way to increase access to new medicines for patients with juvenile idiopathic arthritis, according to a commentary published in Arthritis & Rheumatology.
EULAR: Nurses should be part of rheumatology disease control
Nurses should participate in comprehensive disease management to reduce symptoms and improve outcomes, according to updated EULAR recommendations on the role of nurses in treating inflammatory arthritis.
Lupus heterogeneity tops list of global barriers to advancing care
Disease heterogeneity and the lack of a clear disease definition are among the top barriers to advancing lupus care, according to survey data published in Lupus Science & Medicine.
Filgotinib improves RA signs, symptoms in DMARD-refractory patients
Patients with rheumatoid arthritis who previously had an inadequate response to biologic DMARDs demonstrated improved signs and symptoms after receiving daily doses of filgotinib, according to data published in JAMA.